SGLT2 Inhibitors Treatment Market Segmentation by Application (Glucose Dissipation, Blood Transfusion, Infusion, and Others); and by End-User (Hospitals, Clinics, Diagnostic Center, and Others) – Global Demand Analysis & Opportunity Outlook 2031

Global SGLT2 Inhibitors Treatment Market Highlights over 2022 – 2031

The global SGLT2 inhibitors treatment market is estimated to grow at a notable CAGR over the forecast period, i.e., 2022 – 2031. SGLT2 or sodium glucose cotransporter-2 is used to lower the level of glucose in blood. SGLT2 inhibitors work by inhibiting the kidneys from reabsorbing glucose back into the blood, allowing the excess glucose in the blood to be removed from the body via urine. The growth of the market can be attributed to the increasing prevalence of diabetes across the globe. As per the data by the World Health Organization (WHO), about 422 million people worldwide have diabetes, and 1.5 million deaths can be directly attributed to diabetes each year. Moreover, the growing awareness amongst people regarding diabetes mellitus, and demand for new and effective treatment methods and drugs, are anticipated to further promote the market growth. Furthermore, the growing research activities for the development of new drugs and treatment methods, is estimated to boost the market growth.   

The market is segmented by end-user into hospitals, clinics, diagnostic center, and others out of which, the hospitals segment is anticipated to hold a substantial share in the global SGLT2 inhibitors treatment market over the forecast period on account of increasing popularity of hospitals amongst patients, along with the high patient pool in hospitals. CLICK TO DOWNLOAD SAMPLE REPORT

Major Macro-Economic Indicators Impacting the Market Growth

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global SGLT2 Inhibitors Treatment Market Regional Synopsis

On the basis of geographical analysis, the global SGLT2 inhibitors treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in Asia Pacific region is estimated to witness noteworthy growth over the forecast period on the back of growing cases of diabetes amongst the population, along with rapid improvement in the public healthcare facilities. Moreover, the various government initiatives to curb the prevalence of diabetes, is estimated to boost the market growth.

The market in the North America region is anticipated to gain the largest market share throughout the forecast period owing to the very high prevalence of diabetes in the region. As per the data by the U.S. center for disease control and prevention (CDC), 7.3 million people, which is 11.3% of the total US population, suffer from diabetes.

The global SGLT2 inhibitors treatment market is further classified on the basis of region as follows:

• North America (U.S. & Canada) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

• Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

• Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC (Finland, Sweden, Norway, Denmark), Ireland, Switzerland, Austria, Poland, Turkey, Russia, Rest of Europe), Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

• Asia-Pacific (China, India, Japan, South Korea, Singapore, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

• Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth, Market Players Analysis & Opportunity Outlook

Market Segmentation

Our in-depth analysis of the global SGLT2 inhibitors treatment market includes the following segments:

By Application

• Glucose Dissipation
• Blood Transfusion
• Infusion
• Others

By End-User

• Hospitals
• Clinics
• Diagnostic Centre
• Others

Growth Drivers

• Increasing Prevalence of Diabetes Globally
• Growing Medical R&D Activities

Challenges

• Competition from Existing Diabetes Treatment Drugs
• Lack of Awareness in Middle- and Low-income Regions

Top Featured Companies Dominating the Market

• Novartis International AG
  • Company Overview
  • Business Strategy
  • Key Product Offerings
  • Financial Performance
  • Key Performance Indicators
  • Risk Analysis
  • Recent Development
  • Regional Presence
  • SWOT Analysis 
• Boehringer Ingelheim GmbH
• Janssen Pharmaceutical
• GRUPO TECNIMEDE
• Unichem Laboratories Ltd.
• Edifício Bluepharma
• AstraZeneca Pharmaceuticals LP
• Eli Lilly and Company
• The Merck Group
• Pfizer Inc.